“We don’t stop playing because we grow old, we grow old because we stop playing.”
— Attributed to Oliver Wendell Holmes
This blog is inspired by two consecutive Sunday 40 mile plus bike rides. Another one is planned for next Sunday. By so doing, I am able to avoid the dreadful chaos of day to day news and focus on renewal of body and spirit.
On Tuesdays, I return to my fitness routine so as to best prepare for the next sojourn. Two years ago, none of this would have been possible because of progressive limitations imposed by my hip and knee osteoarthritis. It was in December of 2017 that I underwent regenerative procedures on my knees and January of 2018 when my hips were so treated. Since that time, my only limitation is running but that is attributable to my spine.
The Regenerative Medicine world is about to change; the FDA and FTC are watching. Fast forward to August, 2019 and for those who meet the inclusion criteria in the PSC Clinical Trial, you would not only receive millions of your own stem cells, a quantity will be stored for future use As explained in my last two blogs, the PSC clinical trial is overseen by the FDA anticipating the future of Stem Cell Therapy. Your cells will be reclassified as drug, essentially forcing the stem cell charlatans and camp followers out of practice, actually business.
Unfortunately, up until now, the excitement surrounding emerging stem cell therapy has guided and motivated some patients and health care providers. Stem cell therapies currently used do not contain pure stem cells. Instead, they are a mix of a variety of cells, of which only a very small percentage are stem cells. It is possible that many of these treatments did not contain enough stem cells to help; witness amniotic fluid.
It is also important to recognize that many stem cell therapies now marketed directly to patients are conducted without the required biologics license from the FDA. To make matters worse, some forms of mislabeled stem cell therapies do not contain any living stem cells. Such practices are cause for concern, as these treatments can mislead patients and the public, and delay the scientific progress needed to turn stem cell therapies into cures. When discussing stem cell therapy, it’s important to understand that pure stem cells are not currently available to U.S. patients outside of a clinical research study. We are a first clinical research trial, monitored by the U.S. Food and Drug Administration (FDA), at this time to study stem cell treatment for arthritis.
To learn more, visit my web site at www.sheinkopmd.com. You may schedule a consultation at (847) 390-7666. For more information about the Personalized Stem Cells Trial call (312) 475-1893